CHANGE: E.U. APPROVES AVASTIN FOR OVARIAN CANCER: “The European Commission has approved Roche’s drug Avastin for treating women with newly diagnosed, advanced ovarian cancer, offering new options to sufferers previously limited to surgery and chemotherapy. . . . In two late-stage studies, Roche found that women with newly diagnosed advanced ovarian cancer who used Avastin and chemotherapy and then continued on just Avastin lived quite a bit longer without their disease getting worse compared with those who received only chemotherapy.”